Clinical Trials
5 trialsNCT06598371 2026-05-20
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04262466 2026-03-06
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Phase 1/2 Active not recruiting
NCT06402201 2026-02-27
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
CDR-Life AG
Phase 1 Recruiting
NCT03973333 2024-10-18
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Immunocore Ltd
Phase 1/2 Withdrawn
NCT03515551 2022-03-11
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
Immunocore Ltd
Phase 1/2 Terminated